João Morais, integrated researcher at ciTechCare is the only Portuguese academic and one of the 18 international co-authors of the article ‘New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2024’, published in the European Heart Journal, last March.

The review article summarizes the most relevant studies in cardiovascular pharmacotherapy in 2024, including the approval of first-in-class drugs for the treatment of resistant hypertension and pulmonary arterial hypertension.

Regarding pharmacological safety, the research team highlights the newest data on adverse reactions and drug–drug interactions that may complicate treatment and/or reduce drug adherence, with the consequent decrease in drug effectiveness. Finally, the article presents the most important ongoing phase 2 and phase 3 clinical trials assessing the efficacy and safety of cardiovascular drugs for the prevention and treatment of cardiovascular diseases.

ciTechCare is represented in this study alongside several reference departments of European institutions in the cardiovascular and pharmacology fields, thus contributing to the scientific advancement in this area and, at the same time, to the international recognition of the research center of Polytechnic of Leiria.

The article can be read here: https://doi.org/10.1093/ehjcvp/pvaf012